Re: Discussie rondom Glucosamine
Geplaatst: 24 jan 2012 21:33
De onderzoeksresultaten naar glucosamine zijn wisselend. Ook overzichtsartikelen wijzen niet altijd dezelfde kant op. Als er een significant effect gevonden werd dan was dat vaker voor glucosamine sulphate dan voor glucosamine hydrochloride. Dat onderscheid moet dus zeker gemaakt worden denk ik. Als je van plan bent om glucosamine te nemen zou ik voor de sulphate versie gaan.
Een voordeel is dat het veilig gebruikt kan worden.
Compared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space. Health authorities and health insurers should not cover the costs of these preparations, and new prescriptions to patients who have not received treatment should be discouraged.
http://www.bmj.com/highwire/filestream/ ... _pdf/0.pdf
Heterogeneity among trials of glucosamine is larger than would be expected by chance. Glucosamine hydrochloride is not effective. Among trials with industry involvement, effect sizes were consistently higher. Potential explanations include different glucosamine preparations, inadequate allocation concealment, and industry bias.
http://onlinelibrary.wiley.com/doi/10.1 ... .22728/pdf
This meta-analysis of available data shows that glucosamine and chondroitin sulfate may delay radiological progression of OA of the knee after daily administration for over 2 or 3 years
http://www.springerlink.com/content/r3646q37221x86hg/
Een voordeel is dat het veilig gebruikt kan worden.
Compared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space. Health authorities and health insurers should not cover the costs of these preparations, and new prescriptions to patients who have not received treatment should be discouraged.
http://www.bmj.com/highwire/filestream/ ... _pdf/0.pdf
Heterogeneity among trials of glucosamine is larger than would be expected by chance. Glucosamine hydrochloride is not effective. Among trials with industry involvement, effect sizes were consistently higher. Potential explanations include different glucosamine preparations, inadequate allocation concealment, and industry bias.
http://onlinelibrary.wiley.com/doi/10.1 ... .22728/pdf
This meta-analysis of available data shows that glucosamine and chondroitin sulfate may delay radiological progression of OA of the knee after daily administration for over 2 or 3 years
http://www.springerlink.com/content/r3646q37221x86hg/